Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 704

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 704
---
 |
| Net proceeds from sales of common stock under open market sales agreement                                                   | ​ | ​                  |                  — | ​ | ​ |              1,117 | ​ |
| Proceeds from the exercise of stock options                                                                                 | ​ |                    |                  — | ​ |   |                559 | ​ |
| Net cash (used in) provided by financing activities                                                                         | ​ |                    |             -1,989 | ​ |   |              1,676 | ​ |
| Net (decrease) increase in cash, cash equivalents and restricted cash                                                       | ​ |                    |            -15,122 | ​ |   |                634 | ​ |
| Cash, cash equivalents and restricted cash at beginning of period                                                           | ​ |                    |             53,683 | ​ |   |             64,149 | ​ |
| Cash, cash equivalents and restricted cash at end of period                                                                 | ​ | $                  |             38,561 | ​ | $ |             64,783 | ​ |
| Noncash investing and financing activities                                                                                  | ​ | ​                  |                  ​ | ​ | ​ |                  ​ | ​ |
| Incremental right-of-use asset in exchange for non-cash lease liability from modification of lease                          | ​ | $                  |              3,417 | ​ | $ |                  — | ​ |
| Initial direct costs included as right-of-use asset from modification of lease                                              | ​ | $                  |                577 | ​ | $ |                  — | ​ |
| Accrual for leasehold improvements                                                                                          | ​ | $                  |                  — | ​ | $ |                807 | ​ |

See Notes to Condensed Consolidated Financial Statements.

F- 6

<div align='center'>CARA THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share data)

(unaudited)</div>

1. Business Cara Therapeutics, Inc., or the Company, is a biopharmaceutical corporation formed on July 2, 2004. The Company has been focused on leading a new treatment paradigm to improve the lives of patients suffering from chronic pruritus. The Company’s primary activities to date have been organizing and staffing the Company, developing its lead product and product candidates, including conducting preclinical studies and clinical trials of difelikefalin-based product candidates, and raising capital. On June 14, 2024, the Board of Directors